Lung cancer patients may prefer a quick shot over a long IV
NCT ID NCT05171777
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether people with non-small cell lung cancer prefer getting the drug atezolizumab as a shot under the skin (subcutaneous) or through an IV drip. About 179 patients tried both methods and reported which they liked better. The goal was to see if the shot is more convenient and preferred by patients and healthcare providers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atezolizumab (Tecentriq)
- What this could lead to
- If successful, this could show that a subcutaneous injection is preferred over an IV infusion, making treatment more convenient for patients.
- What could go wrong
- This is a Phase 2 preference study, not a test of effectiveness. The results may not change how well the drug works or apply to all lung cancer patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
A.O.U. Maggiore della Carità
Novara, Piedmont, 28100, Italy
-
Asan Medical Center
Seoul, 05505, South Korea
-
Asante Rogue Regional Medical Center
Medford, Oregon, 97504-8332, United States
-
Azienda Ospedaliera Universitaria Senese
Siena, Abruzzo, 53100, Italy
-
CEMIC
Buenos Aires, C1431FWN, Argentina
-
Centro Oncologico Korben
Ciudad Autonoma Buenos Aires, C1426AGE, Argentina
-
Chungbuk National University Hospital
Cheongju-si, 28644, South Korea
-
Clinica CIMCA
San José, 10103, Costa Rica
-
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña, LA Coruna, 15006, Spain
-
Fundación CENIT para la Investigación en Neurociencias
Buenos Aires, C1125ABD, Argentina
-
Hospital Clinico Universitario Lozano Blesa
Zaragoza, 50009, Spain
-
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, 91350-200, Brazil
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Tenerife, 38320, Spain
-
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, 90035-903, Brazil
-
Hospital de la Santa Creu i Sant Pau
Barcelona, 08041, Spain
-
ICIMED Instituto de Investigación en Ciencias Médicas
San José, 10108, Costa Rica
-
IRCCS Istituto Regina Elena (IFO)
Rome, Lazio, 00144, Italy
-
Instituto Europeo di Oncologia
Milan, Lombardy, 20141, Italy
-
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, 01246-000, Brazil
-
Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy
Otwock, 05-400, Poland
-
New Jersey Hematology Oncology Associates LLC
Brick, New Jersey, 08724-3009, United States
-
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
Ijuí, Rio Grande do Sul, 98700-000, Brazil
-
OrlandiOncología
Santiago, 7500713, Chile
-
Oulun yliopistollinen sairaala (OYS)
Oulu, 90220, Finland
-
Pauls Stradins Clinical University Hospital
R?ga, LV-1002, Latvia
-
Riga East Clinical University Hospital Latvian Oncology Centre
Riga, LV-1079, Latvia
-
Royal Victoria Regional Health Centre
Barrie, Ontario, L4M 6M2, Canada
-
Sault Area Hospital
Sault Ste. Marie, Ontario, P6B 0A8, Canada
-
Tampereen yliopistollinen sairaala (TAYS)
Tampere, 33521, Finland
-
Tri County Hematologyoncology
Massillon, Ohio, 44646-9128, United States
-
Turun yliopistollinen keskussairaala (TYKS)
Turku, 20521, Finland
-
UPMC - Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
Vaasan Keskussairaala
Vaasa, 65130, Finland
-
Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie
Olsztyn, 10-357, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?